title: [Mechanism and effect of cyclooxygenase-2 inhibitor meloxicam on the protection of diabetic nephropathy in rats].
abstract: OBJECTIVE
  To investigate the renal protective effect of specfic cyclooxygenase 2 inhibitor meloxicam on the renal of diabetic nephropathy rats.
  
  
  METHODS
  Twenty-eight Sprague-Dawley (SD) rats with diabetic nephropathy by intraperitoneal injection of streptozotocin were randomly divided into 2 groups: diabetic nephropathy without any treatment (Group D,n = 14), and diabetic nephropathy treated with meloxicam. (Group M,n = 14). Another 12 normal rats were divided into normal control (Group N, n=12), and then Group M began to receive a blocker of cyclooxygenase 2 inhibitor, meloxicam [2 mg/(kg x d)]. Six weeks after the induction of DN, 24 h urine and blood samples were collected and kept at -70 degrees C. Then rats were killed. Their kidneys were removed and longitudinal halved. One half was placed and stored in fixation solution until COX-2 immunohistochemistry was determined.
  
  
  RESULTS
  The creatinine clearance rate, uria protein, and the expression of COX-2 in renal and urinary TXB2 in diabetic rats were significantly higher than in Group N. Meloxicam decreased uria protein or creatinine clearance rate significantly (P < 0.01). Immunohistochemical analysis revealed the decreased expression of COX-2 in the renal of Group M by the meloxicam treatment.
  
  
  CONCLUSIONS
  Meloxicam can protect diabetic kidney, somehow through deceasing the renal expression of COX-2.
authors.affiliation: Department of Nephrology, Xiangya Hospital, Central South University, Changsha 410078, China. lzchun5190@sina.com
authors.forename: Zhi-cun
authors.initials: ZC
authors.lastname: Liu
authors.forename: Qiao-ling
authors.initials: QL
authors.lastname: Zhou
authors.forename: Chun
authors.initials: C
authors.lastname: Ouyang
authors.forename: Sheng-li
authors.initials: SL
authors.lastname: Deng
mesh_terms: D000818:Animals; D051546:Cyclooxygenase 2 / Q000096:biosynthesis* / Q000235:genetics; D052246:Cyclooxygenase 2 Inhibitors / Q000494:pharmacology*; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy; D003928:Diabetic Nephropathies / Q000188:drug therapy* / Q000201:enzymology; D007668:Kidney / Q000201:enzymology*; D008297:Male; D000077239:Meloxicam; D020011:Protective Agents / Q000494:pharmacology; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D013843:Thiazines / Q000494:pharmacology*; D013844:Thiazoles / Q000494:pharmacology*
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D020011:Protective Agents; D013843:Thiazines; D013844:Thiazoles; D051546:Cyclooxygenase 2; D000077239:Meloxicam